Ola Azzouqah, MD
Rheumatology · Albuquerque, NMNPI 1366854044
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $952 of the $1,120 with a category attached, or 85.0%. 8 manufacturers reported payments, led by AbbVie at 38.8% of the total. Reporting peaked in 2019 at $606 and has fallen 63.1% since, to $224 in 2025. That places this record below the midpoint for rheumatology clinicians in NM, where the typical reported total is $1,560.
Across 28 payments — averaging $40.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$434
- Amgen$339
- GSK$195
- UCB, Inc.$69
- Boehringer Ingelheim$34
- Sobi, Inc$19
- plus $31 from 2 others
What the payments were for
- Food & beverage$95285%
- Education$16815%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 8 | $434 |
| Amgen(2 entities) | 7 | $339 |
| GSK | 6 | $195 |
| UCB, Inc. | 2 | $69 |
| Boehringer Ingelheim | 2 | $34 |
| Sobi, Inc | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,120 in reported general payments places this provider in the 40th percentile of 44 rheumatology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 69 | $502,161 |
| Humira(Cf) PenAdalimumab | 61 | $446,647 |
| Skyrizi PenRisankizumab-Rzaa | 13 | $277,176 |
| Amjevita(Cf) AutoinjectorAdalimumab-Atto | 75 | $235,466 |
| Actemra ActpenTocilizumab | 51 | $216,990 |
| OrenciaAbatacept | 32 | $177,953 |
| EnbrelEtanercept | 21 | $154,612 |
| Orencia ClickjectAbatacept | 24 | $133,061 |
| Xeljanz XrTofacitinib Citrate | 22 | $118,565 |
| Cosentyx Unoready PenSecukinumab | 13 | $105,133 |
| OtezlaApremilast | 18 | $98,631 |
| ActemraTocilizumab | 24 | $84,658 |
| Humira PenAdalimumab | 11 | $74,928 |
| RinvoqUpadacitinib | 11 | $69,031 |
| KevzaraSarilumab | 12 | $50,891 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel, Otezla | $339 | $253,24339 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $19 | $177,95332 claims |
| AbbVieRinvoq | $434 | $69,03111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 44 rheumatology providers in New Mexico.
Other rheumatology in Albuquerque
- Wilmer SibbittAlbuquerque$9K
- Leroy PachecoAlbuquerque$8K
- Albert RizzoliAlbuquerque$7K
- Scott StoernerAlbuquerque$5K
- Andres PeisajovichAlbuquerque$4K
- Sabeen YaqubAlbuquerque$4K
- Mirza BegAlbuquerque$4K
- Ahsan IqbalAlbuquerque$3K
- Peter RosandichAlbuquerque$2K
- Juliet CoquiaAlbuquerque$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.